In the aforementioned research article published in the May 2021 issue of the European Respiratory Journal, the epithelial lining fluid (ELF) data used in figure 2c and d was calculated in error from an incorrect bronchoalveolar lavage (BAL) fluid data set. The incorrect data was from the resuspended BAL cell preparation rather than the true BAL fluid concentrations in the supernatant generated post-BAL cell centrifugation. The correct data from the BAL fluid supernatants following the removal of BAL cells has now been used to calculate the ELF data and this has been corrected in figure 2c and d. The caption to figure 2 has also been updated to reflect these changes. These corrections do not impact the interpretation of the data or the conclusions of the paper, and no other parts of the article have been affected by this correction.
The new figure with the updated caption is below, and the article has been corrected and republished online.
TD139 pharmacokinetics in healthy subjects and idiopathic pulmonary fibrosis (IPF) patients. ELF: epithelial lining fluid; AM: alveolar macrophage. a) Healthy subjects: log-linear mean plasma concentration of TD139 versus time over 48 h following a single dose of drug. b) IPF patients: log-linear mean plasma concentration of TD139 versus time over 24 h following the first dose of drug on day 1 or the last dose on day 14. c) Log-linear individual measured concentrations (median) in plasma (total), ELF and AMs at 2 h post-administration of 0.3, 3 and 10 mg TD139 on day 14. d) Correlation between concentrations of TD139 in ELF and AMs for all active cohorts on day 14 (r=0.87 (95% CI 0.56–0.96); p<0.001). e) Correlation between concentrations of TD139 in plasma (total) and AMs for all active cohorts on day 14 (r=0.89 (95% CI 0.65–0.96); p<0.0001). Shading represents 95% CI of the linear fit. For reference, the lower limit of detection in plasma was 0.5 ng·mL−1 and in BAL fluid was 5 ng·mL−1.
- Copyright ©ERS 2022.
